[HTML][HTML] Dupilumab in persistent asthma with elevated eosinophil levels

S Wenzel, L Ford, D Pearlman, S Spector… - New England journal …, 2013 - Mass Medical Soc
S Wenzel, L Ford, D Pearlman, S Spector, L Sher, F Skobieranda, L Wang, S Kirkesseli…
New England journal of medicine, 2013Mass Medical Soc
Background Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy
and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the
alpha subunit of the interleukin-4 receptor, in patients with persistent, moderate-to-severe
asthma and elevated eosinophil levels. Methods We enrolled patients with persistent,
moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter
or a sputum eosinophil level of at least 3% who used medium-dose to high-dose inhaled …
Background
Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, moderate-to-severe asthma and elevated eosinophil levels.
Methods
We enrolled patients with persistent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter or a sputum eosinophil level of at least 3% who used medium-dose to high-dose inhaled glucocorticoids plus long-acting beta-agonists (LABAs). We administered dupilumab (300 mg) or placebo subcutaneously once weekly. Patients were instructed to discontinue LABAs at week 4 and to taper and discontinue inhaled glucocorticoids during weeks 6 through 9. Patients received the study drug for 12 weeks or until a protocol-defined asthma exacerbation occurred. The primary end point was the occurrence of an asthma exacerbation; secondary end points included a range of measures of asthma control. Effects on various type 2 helper T-cell (Th2)–associated biomarkers and safety and tolerability were also evaluated.
Results
A total of 52 patients were assigned to the dupilumab group, and 52 patients were assigned to the placebo group. Baseline characteristics were similar in the two groups. Three patients had an asthma exacerbation with dupilumab (6%) versus 23 with placebo (44%), corresponding to an 87% reduction with dupilumab (odds ratio, 0.08; 95% confidence interval, 0.02 to 0.28; P<0.001). Significant improvements were observed for most measures of lung function and asthma control. Dupilumab reduced biomarkers associated with Th2-driven inflammation. Injection-site reactions, nasopharyngitis, nausea, and headache occurred more frequently with dupilumab than with placebo.
Conclusions
In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT01312961.)
The New England Journal Of Medicine